The Manufacturers Life Insurance Company cut its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 18.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,777 shares of the biopharmaceutical company's stock after selling 24,010 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.16% of Celldex Therapeutics worth $3,595,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in shares of Celldex Therapeutics by 51.0% in the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock worth $71,725,000 after purchasing an additional 654,194 shares during the period. Marshall Wace LLP increased its holdings in Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after buying an additional 479,068 shares during the period. Jennison Associates LLC increased its holdings in Celldex Therapeutics by 32.0% in the 3rd quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock valued at $45,017,000 after buying an additional 321,325 shares during the period. Novo Holdings A S raised its position in shares of Celldex Therapeutics by 13.4% in the 3rd quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock valued at $32,755,000 after buying an additional 113,663 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its holdings in shares of Celldex Therapeutics by 47.5% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 845,560 shares of the biopharmaceutical company's stock worth $31,294,000 after acquiring an additional 272,389 shares during the period.
Celldex Therapeutics Trading Up 2.7 %
CLDX stock traded up $0.71 during trading on Friday, hitting $26.77. The company had a trading volume of 1,457,491 shares, compared to its average volume of 969,469. The stock has a market cap of $1.78 billion, a PE ratio of -10.42 and a beta of 1.57. The business has a 50-day moving average of $27.80 and a 200-day moving average of $33.97. Celldex Therapeutics, Inc. has a one year low of $22.93 and a one year high of $53.18.
Insider Transactions at Celldex Therapeutics
In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The stock was acquired at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the purchase, the chief executive officer now directly owns 40,284 shares of the company's stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 3.80% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Several research firms have weighed in on CLDX. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a "neutral" rating and a $45.00 target price on the stock. Wells Fargo & Company raised shares of Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Finally, Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a "buy" rating and a $70.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.25.
Read Our Latest Stock Report on Celldex Therapeutics
Celldex Therapeutics Company Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
See Also
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
